Healthcare is undergoing a seismic shift from reactive treatment to predictive prevention and longevity. We invest in companies leveraging AI, genomics, regenerative medicine, and neurotechnology to eliminate disease, reverse aging, and extend healthy lifespans to 120+ years. Our portfolio is pioneering the biotechnology infrastructure for century-long healthspans.
AI-powered drug discovery platforms like Atomwise and Verge Genomics reduce development timelines from 15+ years to 3-5 years, accelerating breakthroughs in cancer, Alzheimer’s, and rare diseases.
10x
Faster drug discovery through AI and machine learning platforms
Companies like HexemBio and Stamm Bio are pioneering regenerative stem cell therapies and advanced biomanufacturing platforms, driving a new era of medicine that may extend healthy human lifespans by 20 to 30 years.
20-30
Additional healthy years of lifespan from breakthrough longevity therapies
Since 2015, Draper has backed genomics pioneers like Form Bio and Ten63 Therapeutics, developing personalized therapies and diagnostics that prevent disease based on individual genetic profiles.
2015
Year Draper began major investments in precision medicine and genomics
The future of medicine is shifting from treating disease to preventing, reversing, and even eliminating it altogether. With the convergence of AI, genetics, regenerative medicine, and human-machine interfaces, we are entering an era where chronic conditions could become a thing of the past, aging could be slowed or reversed, and cells could be programmed like software.
AI platforms from Atomwise and Verge Genomics are revolutionizing how we discover new medicines, analyzing millions of molecular interactions to accelerate breakthroughs in cancer, Alzheimer's, and rare diseases. What once took 15+ years can now be compressed into significantly shorter timelines through intelligent automation.
Companies like Phantom Neuro and Precision Neuro are developing brain-computer interfaces that unlock new frontiers in human potential—enhancing cognition, restoring lost function, and bridging the gap between biology and technology. These innovations are redefining healthcare from treating neurodegenerative diseases to enabling direct communication between the brain and external devices.
Form Bio and Ten63 Therapeutics are pioneering computational approaches to develop personalized treatments, targeting previously "undruggable" proteins and creating therapies tailored to individual genetic profiles. This represents medicine becoming truly personalized, proactive, and preventative.
HexemBio and Stamm Bio are advancing stem cell therapies and biomanufacturing technologies that could extend healthy lifespans. While we're still in early stages, these breakthrough therapies show promise for cellular rejuvenation and tissue repair at unprecedented scales.
We back companies developing AI-driven drug discovery, brain-computer interfaces, regenerative medicine, synthetic biology, and preventative healthcare solutions. We invest in founders who don't just want to improve medicine—they want to reinvent it entirely.
Our healthcare portfolio includes Form Bio (AI drug discovery), Ten63 Therapeutics (computational drug discovery targeting undruggables), Verge Genomics (AI-driven neurological disease research), Atomwise (AI-powered therapeutics), HexemBio (stem cell therapy), Precision Neuro and Phantom Neuro (brain-computer interfaces), Stamm Bio (advanced biomanufacturing), and Trestle Bio (implantable therapeutics). These companies are building the foundation for a world where medicine is personalized, proactive, and preventative.
We continue to seek out companies pushing the boundaries of regenerative medicine, longevity research, AI-powered drug discovery, synthetic biology, human-machine interfaces, and healthcare accessibility. The companies that harness these technologies today will set the foundation for a world where severe and chronic diseases are a relic of the past.